Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Citi
QuintilesIMS
AstraZeneca
Boehringer Ingelheim
Teva

Generated: July 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,265,720

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,265,720 protect, and when does it expire?

Patent 9,265,720 protects EDLUAR and is included in one NDA.

This patent has twenty patent family members in twelve countries.

Summary for Patent: 9,265,720
Title:Pharmaceutical formulations useful in the treatment of insomnia
Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.
Inventor(s): Pettersson; Anders (Kode, SE), Nystrom; Christer (Stockholm, SE), Bredenberg; Susanne (Uppsala, SE)
Assignee: Orexo AB (Uppsala, SE)
Application Number:11/666,361
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,265,720
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation; Device;

Drugs Protected by US Patent 9,265,720

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan Speciality Lp EDLUAR zolpidem tartrate TABLET;SUBLINGUAL 021997-001 Mar 13, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET ➤ Sign Up
Mylan Speciality Lp EDLUAR zolpidem tartrate TABLET;SUBLINGUAL 021997-002 Mar 13, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,265,720

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0423800.2Oct 27, 2004
PCT Information
PCT FiledOctober 26, 2005PCT Application Number:PCT/GB2005/004147
PCT Publication Date:May 04, 2006PCT Publication Number: WO2006/046041

International Family Members for US Patent 9,265,720

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus 1118414 ➤ Sign Up
Cyprus 1119580 ➤ Sign Up
Denmark 1807156 ➤ Sign Up
Denmark 2340872 ➤ Sign Up
European Patent Office 1807156 ➤ Sign Up
European Patent Office 2340872 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Healthtrust
Queensland Health
Accenture
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.